Priothera
  • Home
  • Science
    • Mocravimod
    • Acute Myeloid Leukemia & Hematopoietic Cell Transplantation
    • CAR T Cells
    • Our Pipeline
    • Publications
  • MO-TRANS
  • Press
  • About
    • Our Leadership Team
    • Advisory Board
    • Investors
    • Our Partners
    • ESG and Recognition
  • Contact
Select Page

Mocravimod improves overall survival in AML patients undergoing allogeneic hematopoietic cell transplantation

by admin | Jun 1, 2023 | Exploring Mocravimod Key Research Highlights

https://priotherabk.raredev.co.uk/mocravimod-improves-overall-survival-in-aml-patients-undergoing-allogeneic-hematopoietic-cell-transplantation/

Priothera, Adding Quality Years to Life

Get In Touch

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland

© Priothera Ltd. 2025

Priothera SAS
57 Avenue Général de Gaulle
68300 Saint-Louis, France

Priothera Ltd
88 Harcourt Street, Dublin 2,
D02 DK18, Ireland